Reducing cancer deaths to zero with HPV vaccination

In England, a groundbreaking study has revealed that there were zero deaths from cervical cancer among women aged between 20 and 24 years during the period from 2020 to 2024. This remarkable achievement is attributed to the widespread use of the HPV vaccine, which protects against certain strains of the human papillomavirus (HPV), a primary cause of cervical cancer. The research, published in a major medical journal, highlights how the introduction of the HPV vaccination program in 2008 has significantly reduced mortality rates associated with this disease. According to the findings, approximately 200 lives have been saved due to the vaccine’s effectiveness over the years. Before the implementation of the vaccination campaign, around 20 deaths per year were recorded within this age group alone.

The study was conducted by researchers at Queen Mary University in London, led by Professor Peter Sasieni. He emphasized the incredible impact of the vaccine, stating that even a single dose can nearly eliminate a specific type of cancer. However, he also warned that while the current success is significant, it represents just the tip of the iceberg. As the vaccinated generations grow older, more lives will likely be saved from cervical cancer. Sasieni stressed the importance of maintaining high vaccination rates to ensure continued protection for future populations.

Cervical cancer remains the 14th most common cancer among women in the United Kingdom, with about 3,300 new cases diagnosed annually. Nearly all instances of this cancer are linked to HPV infection, which spreads through close skin-to-skin contact. While most HPV infections resolve on their own within one to two years, persistent infections can lead to cellular changes that eventually result in cancer. Despite the availability of the vaccine, regular gynecological screenings remain essential, as the vaccine does not protect against all types of HPV.

Despite these successes, recent data indicates that vaccination rates in England have fallen below recommended levels. Last year, only 76 percent of girls under the age of 15 received the HPV vaccine, compared to the World Health Organization's target of 90 percent needed to eradicate cervical cancer. Boys have also been eligible for the HPV vaccine since 2019, which helps prevent cancers of the anus, penis, throat, and mouth, as well as reducing the risk of transmitting the virus to girls.

In Slovenia, the HPV vaccine has been free for all girls in the sixth grade of elementary school since 2009, and since 2021, it has also been available for boys in the same grade. According to the European Association of Women's Health, cervical cancer accounts for approximately 1.5 percent of all newly diagnosed cancers in Slovenia. Thanks to effective early detection and treatment programs such as ZORA, the incidence rate has nearly halved in recent years. In 2022, 97 women were newly diagnosed with cervical cancer, and 32 died from it, placing Slovenia among countries with the lowest prevalence and mortality rates from this disease.

The success story of England’s HPV vaccination program has inspired other nations to adopt similar strategies. However, challenges persist, particularly in ensuring consistent vaccination coverage across all demographics. Public health officials continue to emphasize the need for ongoing education and outreach efforts to maintain high vaccination rates and ultimately achieve the goal of eliminating cervical cancer as a public health issue by 2040.

Personal stories further illustrate the real-world impact of the HPV vaccine. Alexandra Legg, who was diagnosed with cervical cancer at the age of 30, shared her experience of undergoing surgery to remove lymph nodes in her abdomen. Although surgeons managed to preserve part of her cervix, allowing her to carry a child, she described the emotional toll of the diagnosis and treatment. Reflecting on her journey, she expressed regret that the HPV vaccine was not available to her at the time. Her story serves as a powerful reminder of the importance of vaccination and the potential benefits it offers to individuals and communities alike.

Looking ahead, experts anticipate a continued decline in cervical cancer-related deaths as more people receive the HPV vaccine. However, achieving the long-term goal of eradicating cervical cancer requires sustained commitment from governments, healthcare providers, and the public. Ongoing research and monitoring will be crucial in assessing the effectiveness of current vaccination strategies and identifying areas where improvements are needed. With continued progress, the dream of a world without cervical cancer may become a reality in the near future.